The study shows that HER2-positive tumors that were sensitive to trastuzumab treatment had a higher expression of certain chemokines related to an antitumor immune response, to migration of T and B lymphocytes to the tumor bed and monocyte recruitment. This evidence concerns the gene ERBB2 and neoplasm.